Media.Player

Surfactant Based Tobramycin Solution for Inhalation

Detailed Technology Description

None

*Abstract

The inventors are considering whether the inhaled medications currently being used to treat cystic fibrosis might be improved through the addition of specific dispersion agents that might improve how medications are distributed over the internal surfaces of the lungs after they are inhaled and deposited in the lungs. Improving the dispersion of these drugs would allow them to reach more sites of infection in the lung ultimately making them more effective. These dispersion agents could also be used to improve the efficacy of other inhaled medications for conditions such as asthma, chronic obstructive pulmonary disease (COPD), or lung transplant rejection.The inventors have created a new surfactant based version of a commonly used inhaled antibiotic. It is believed that the surfactant base will improve drug efficacy by better dispersing the active drug agent through the lungs.Applications:1) Treatment of pulmonary infections associated with cystic fibrosis2) Treatment of nosocomial infections seen in intensive careAdvantages:1) Surfactant based formulation improves drug efficacy by more effectively dispersing the amount of active drug through the lungs2) This type of formulation could be applied to create new forms of many other inhaled drugs to improve efficacy.3) Despite the obvious advantages of inhaling an antibiotic to treat pulmonary infection, only one approved preparation is currently available.Non Provisional and PCT Patent Applications Filed

*Principal Investigator

Name: Timothy Corcoran

Department: Med-Medicine

Name: Amy Marcinkowski

Department: Bioengineering

Name: Joseph Pilewski

Department: Med-Medicine

Name: Kristina Thomas

Department: Chem/Petroleum Engineering

Country/Region

USA